Retatrutide: The Triple Agonist Pushing Weight Loss Past Everything Before It

Overview

Retatrutide (development code LY3437943) is the compound everyone in the metabolic space is watching. It is an investigational Eli Lilly peptide that hits three hormone receptors at once, and in clinical trials it has produced the largest weight reductions ever reported for an incretin-based drug. In the pivotal phase 2 obesity trial, the top dose drove placebo-adjusted weight loss of roughly 24% over 48 weeks [1]. Topline phase 3 data announced in 2026 push that figure even higher, with mean weight loss reported up to around 30% at two years [11][12].

For self-experimenters, retatrutide is unusual: unlike most peptides discussed in this community, it carries genuinely strong, high-quality human evidence behind it. But it is also unapproved, still in late-stage trials, and the long-term safety picture is not yet complete. This article walks through what the published research actually shows, where the gaps are, and what the community is reporting.

What it is & how it works

Retatrutide is a single synthetic peptide engineered to activate three different gut and pancreatic hormone receptors simultaneously, which is why it is called a "triple agonist" or "triagonist" [7]. The three targets are:

• GLP-1 receptor — slows gastric emptying, boosts glucose-dependent insulin secretion, and suppresses appetite through central nervous system pathways [7].
• GIP receptor — adds further insulin-stimulating effect and is thought to improve nausea tolerability and the way the body handles fat tissue [7].
• Glucagon receptor — the novel third lever, believed to increase energy expenditure and drive hepatic fat oxidation and lipolysis [7].

The first two receptors are the same ones hit by tirzepatide (a dual agonist). The glucagon component is what sets retatrutide apart. Where GLP-1 and GIP mainly reduce how much you eat, glucagon-receptor activation is thought to increase how much energy you burn and how aggressively the liver mobilises fat [7]. That combination — lower intake plus higher expenditure — is the leading explanation for both the exceptionally large reductions in liver fat and the weight loss that exceeds what GLP-1 mono- and dual-agonists achieve [7].

What the published research says

The evidence base here is strong by peptide-research standards, anchored by three peer-reviewed phase 2 trials and multiple meta-analyses.

Obesity (NEJM, 2023). The pivotal phase 2 randomised controlled trial enrolled 338 adults with obesity. At 48 weeks, placebo-adjusted weight loss climbed with dose: about 8.7% at 1 mg, 17.1% at 4 mg, 22.8% at 8 mg, and 24.2% at 12 mg, versus 2.1% on placebo. At the top dose, 83% of participants lost at least 15% of their body weight. Gastrointestinal side effects were dose-related but mostly mild to moderate [1].

Type 2 diabetes (Lancet, 2023). A separate phase 2 RCT in 281 adults with type 2 diabetes showed HbA1c falling by up to about 2.0% at 24 weeks, alongside weight loss of roughly 17% at 36 weeks — outperforming the active comparator dulaglutide 1.5 mg, with no severe hypoglycaemia and no deaths [2].

Liver fat (Nature Medicine, 2024). A MASLD substudy of 98 participants found liver-fat reductions ranging from about 43% at 1 mg to a striking 82% at 12 mg over 24 weeks, versus essentially no change on placebo. By the top dose, 86% of participants reached normal liver fat (under 5%) [3].

The bigger picture. A systematic review of 26 RCTs covering 15,491 participants and 12 different agents (Annals of Internal Medicine, 2025) found retatrutide 12 mg produced the greatest weight loss of any GLP-1-based drug studied — up to 22.1% at 48 weeks, ahead of tirzepatide (17.8%) and semaglutide (13.9%) [4]. Two further meta-analyses corroborate the magnitude: one reported a mean weight reduction of about 14.3% across three RCTs [5], and another found participants were roughly 18 times more likely to lose at least 15% of body weight than those on placebo [6]. A pipeline review noted the results approach bariatric-surgery-level weight loss [10].

A crucial caveat: there are no head-to-head RCTs comparing retatrutide directly against semaglutide or tirzepatide [4][9]. Every comparison above is a cross-trial inference, not a direct contest, so the rankings should be read with that limitation in mind.

Phase 3 (2026, topline only). Lilly has announced topline results from the phase 3 TRIUMPH-1 obesity trial: 12 mg delivered about 28.3% mean weight loss at 80 weeks, rising to up to 30.3% (an average of roughly 85 lb) at 104 weeks in a higher-BMI extension [11][12]. These figures are from a press release and conference coverage — they are not yet fully peer-reviewed, and additional readouts (TRIUMPH-2 in diabetes, TRIUMPH-3 in cardiovascular disease) remain pending. Treat phase 3 numbers as promising but provisional.

Dose & Exposure Context

Members only

Detailed exposure data is available to members

Research Rats reports dose and exposure figures as evidence context, not use instructions. The detailed section sets out what quantities were licensed, studied, or reported, each tied to its source:

• Regulated Prescribing Context
• Human Clinical Exposure
• Preclinical Exposure
• Community-Reported Exposure Patterns
• Interpretation

Regulatory status, evidence strength and safety context above remain public.

Sign in or create an account

Safety & considerations

The most consistent safety signal across every trial is gastrointestinal. These effects are dose-related and largely mild to moderate, but they are common: in TRIUMPH-1, nausea reached around 42%, vomiting about 25%, diarrhoea 32%, and constipation 26% at the 12 mg dose versus placebo [12]. AE-driven discontinuation was 11.3% at 12 mg versus 4.9% on placebo [11].

Beyond the gut, several considerations deserve attention:

• Heart rate. A dose-dependent increase in heart rate (up to roughly 6–7 bpm in phase 2) is a recognised concern [9]. Cardiovascular outcome data are still being generated in the ongoing phase 3 TRIUMPH-3 trial.
• Glucose. Glucagon-receptor activation can transiently raise blood glucose. In trials the net effect was still strongly glucose-lowering, thanks to the GLP-1 and GIP components, but glycaemic effects warrant monitoring [2].
• Class-level risks. Authoritative reviews of incretin drugs flag possible loss of lean and muscle mass during rapid weight loss, delayed gastric emptying relevant to anaesthesia and aspiration risk, and potential pancreatic or biliary events [8]. Long-term data specific to retatrutide remain immature.
• Population limits. Trial participants were adults with obesity and/or type 2 diabetes under medical supervision. Safety in pregnancy, adolescents, and other groups is not established.

The bottom line

Retatrutide stands out for two reasons. First, the efficacy data are genuinely exceptional — the largest weight reductions reported for any incretin agent, backed by three peer-reviewed phase 2 trials, multiple meta-analyses, and now topline phase 3 results approaching bariatric-surgery territory [1][3][4][10][11]. Second, that evidence is far stronger and more transparent than what backs most compounds discussed in self-experimentation circles.

But the honest framing matters. The drug is still investigational, the standout phase 3 figures are press-release-level and not yet fully peer-reviewed [11][12], long-term cardiovascular and outcome data are still maturing, and every claim that it beats semaglutide or tirzepatide rests on cross-trial comparison rather than a direct contest [4][9]. The triple-agonist mechanism that makes it so powerful — particularly the glucagon arm — also introduces the heart-rate and glucose considerations that distinguish it from simpler GLP-1 drugs [7][9]. Anyone weighing the evidence should keep both the remarkable numbers and the unresolved questions firmly in view.